These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
91 related items for PubMed ID: 12208412
1. Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, Pak R, Rasmussen H, Crystal R. Am J Cardiol; 2002 Sep 01; 90(5):512-6. PubMed ID: 12208412 [Abstract] [Full Text] [Related]
2. Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Rajagopalan S, Mohler ER, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH. Circulation; 2003 Oct 21; 108(16):1933-8. PubMed ID: 14504183 [Abstract] [Full Text] [Related]
6. Vascular permeability effect of adenovirus-mediated vascular endothelial growth factor gene transfer to the rabbit and rat skeletal muscle. Poliakova L, Kovesdi I, Wang X, Capogrossi MC, Talan M. J Thorac Cardiovasc Surg; 1999 Aug 21; 118(2):339-47. PubMed ID: 10425008 [Abstract] [Full Text] [Related]
7. Regional angiogenesis induced in nonischemic tissue by an adenoviral vector expressing vascular endothelial growth factor. Magovern CJ, Mack CA, Zhang J, Rosengart TK, Isom OW, Crystal RG. Hum Gene Ther; 1997 Jan 20; 8(2):215-27. PubMed ID: 9017425 [Abstract] [Full Text] [Related]
8. Differential effects of cilostazol and pentoxifylline on vascular endothelial growth factor in patients with intermittent claudication. Lee TM, Su SF, Tsai CH, Lee YT, Wang SS. Clin Sci (Lond); 2001 Sep 20; 101(3):305-11. PubMed ID: 11524048 [Abstract] [Full Text] [Related]
9. Six-month assessment of a phase I trial of angiogenic gene therapy for the treatment of coronary artery disease using direct intramyocardial administration of an adenovirus vector expressing the VEGF121 cDNA. Rosengart TK, Lee LY, Patel SR, Kligfield PD, Okin PM, Hackett NR, Isom OW, Crystal RG. Ann Surg; 1999 Oct 20; 230(4):466-70; discussion 470-2. PubMed ID: 10522716 [Abstract] [Full Text] [Related]
10. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Hedman M, Hartikainen J, Syvänne M, Stjernvall J, Hedman A, Kivelä A, Vanninen E, Mussalo H, Kauppila E, Simula S, Närvänen O, Rantala A, Peuhkurinen K, Nieminen MS, Laakso M, Ylä-Herttuala S. Circulation; 2003 Jun 03; 107(21):2677-83. PubMed ID: 12742981 [Abstract] [Full Text] [Related]
11. Intramuscular vascular endothelial growth factor gene therapy in patients with chronic critical leg ischemia. Shyu KG, Chang H, Wang BW, Kuan P. Am J Med; 2003 Feb 01; 114(2):85-92. PubMed ID: 12586226 [Abstract] [Full Text] [Related]
15. Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions. Harvey BG, Maroni J, O'Donoghue KA, Chu KW, Muscat JC, Pippo AL, Wright CE, Hollmann C, Wisnivesky JP, Kessler PD, Rasmussen HS, Rosengart TK, Crystal RG. Hum Gene Ther; 2002 Jan 01; 13(1):15-63. PubMed ID: 11779412 [Abstract] [Full Text] [Related]
16. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK, Willerson JT, Benza RL, Berman DS, Gibson CM, Bajamonde A, Rundle AC, Fine J, McCluskey ER, VIVA Investigators. Circulation; 2003 Mar 18; 107(10):1359-65. PubMed ID: 12642354 [Abstract] [Full Text] [Related]
17. Direct in vivo gene transfer to canine myocardium using a replication-deficient adenovirus vector. Magovern CJ, Mack CA, Zhang J, Hahn RT, Ko W, Isom OW, Crystal RG, Rosengart TK. Ann Thorac Surg; 1996 Aug 18; 62(2):425-33; discussion 433-4. PubMed ID: 8694601 [Abstract] [Full Text] [Related]
18. Improving walking ability and ankle brachial pressure indices in symptomatic peripheral vascular disease with intermittent pneumatic foot compression: a prospective controlled study with one-year follow-up. Delis KT, Nicolaides AN, Wolfe JH, Stansby G. J Vasc Surg; 2000 Apr 18; 31(4):650-61. PubMed ID: 10753272 [Abstract] [Full Text] [Related]
19. Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease. Grossman PM, Mendelsohn F, Henry TD, Hermiller JB, Litt M, Saucedo JF, Weiss RJ, Kandzari DE, Kleiman N, Anderson RD, Gottlieb D, Karlsberg R, Snell J, Rocha-Singh K. Am Heart J; 2007 May 18; 153(5):874-80. PubMed ID: 17452167 [Abstract] [Full Text] [Related]
20. Analysis of risk factors for local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of comorbid conditions. Crystal RG, Harvey BG, Wisnivesky JP, O'Donoghue KA, Chu KW, Maroni J, Muscat JC, Pippo AL, Wright CE, Kaner RJ, Leopold PL, Kessler PD, Rasmussen HS, Rosengart TK, Hollmann C. Hum Gene Ther; 2002 Jan 01; 13(1):65-100. PubMed ID: 11779413 [Abstract] [Full Text] [Related] Page: [Next] [New Search]